3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Neoplasms
27
Colorectal Neoplasms
20
Breast Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
13
Neoplasm Metastasis
12
Lung Neoplasms
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Melanoma
9
Lymphoma, Non-Hodgkin
8
Small Cell Lung Carcinoma
6
Recurrence
6
Liver Neoplasms
6
Leukemia
6
Head and Neck Neoplasms
6
Fallopian Tube Neoplasms
6
Prostatic Neoplasms
5
Glioblastoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Gastrointestinal Neoplasms
4
Uterine Cervical Neoplasms
3
Interventions
pembrolizumab
51
Nivolumab
27
Gemcitabine
23
atezolizumab
19
Cisplatin
18
Carboplatin
18
enfortumab vedotin
15
avelumab
15
Mitomycin
14
Docetaxel
8
Ipilimumab
7
Paclitaxel
6
Injections
5
Cyclophosphamide
5
vinflunine
4
toripalimab
4
tislelizumab
4
lenvatinib
4
fludarabine
4
epacadostat
4
Pemetrexed
4
130-nm albumin-bound paclitaxel
4
sacituzumab govitecan
3
disitamab vedotin
3
Rogaratinib
3
Interleukin-2
3
ALT-803
3
vofatamab
2
valrubicin
2
rucaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Transitional Cell
×
Drug Therapy
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts